7. 5. 2013 - FAVEA USES MODERN TECHNOLOGIES

At the end of the 20th century, the pharmaceutical company Favea a. s., based in Kopřivnice, Czech Republic, set a goal to increase the quality as well as the utility value of its newly developed products through the progressive technology of particle micronization (the decrease of size from millimeters to micrometers). mikro2_1291_02The micro-grinding of a number of medici substances, vitamins and minerals, as well as dry plant extracts, or their components for cosmetic products, were tested with laboratory equipment. As soon as Favea products labeled “μ” – micronization appeared, thein overextended laboratory equipment exceeded its capacity and the company purchased production equipment.

Professionals from the cosmetic industry knew very well that they would be considerably more successful if the sharp edges of pigments for decorative cosmetics were removed through micronization. The female skin is particularly sensitive to those sharp edges and, additionally, they required smaller amounts of pigment to achieve more intensive tones. (We also learned that a modern woman uses 2 to 5 kilos of lipstick over a lifetime of make-up).

When Favea set up its operation with a micronization line and supplemented it by equipment for concurrent drying and a freezing unit, it was able to obtain microparticles with more uniformity in terms of particle distribution and very low moisture content. At the same time, the company created the conditions for lower occurrences of agglomerated micronized particles. They further developed processes using micronized active substances, by technology that produced tablets with very fast disintegration and the immediate absorption of micronized active ingredients in the user’s oral cavity. These are the actual properties of the substances effecting so-called “biological availability.”

Through substance micronization and the use of "high-tech fluid jets", it is possible to achieve a 5 micron particle size reduction limit and significantly increase the surface (for example, from the initial substance with particles of 600μm, the number of particles ground to the size of 5 μm increases 1,750,000-times and the surface increases 120-times). The increase in bioavailability can more easily get the substance into the circulatory system, achieving higher dissolution rates and faster absorption. The possible adjustment of dosages ensures the same effect, as well as lower occurrences of negative side effects. These adjustments may lead to achieving bioequivalence with the selected standard medication.

We cannot micronize substances with low thawing points or those that are in a liquid form under normal temperatures. We have therefore developed a different method for liquid and semi-liquid fillings, called hard capsules. The capsule material is not a gelatin, but plant materials. With only one dosage of medication per day, it is possible to achieve either nearly immediate effects (faster than effervescent tablets) or, on the other hand, a long-term effect.

Quite often an active ingredient in the form of powder must be added to the oil and this is where problems arise in traditional medications, because from 20% concentrations on, the mixture acts like a paste (even tooth paste has approximately 20% of solid substances and the balance is water). The blood of animals contains approximately 50% solid particles (red blood cells in plasma). Favea developed a method to enable the capsule to contain up to 80% solid particles.

They cannot say we have exceeded nature, but in this single case, they came close to it... Severely ill patients should particularly benefit from this and that was their goal. For more technical details, visit www.combicaps.com

By PharmDr. Milan Krajíček

Interviews.